Physician profile
Todd Terzo
NPI 1396700175
$5,013.37
in general payments reported to CMS, 2019-2025
31 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $780 · 2023: $1,092 · 2024: $1,671 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,216 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,216.33 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,183.14 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $528.84 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $377.69 | 2023-2025 | |
| Amgen INC. | $374.71 | 2022-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $303.76 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.21 | 2023-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $292.66 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.01 | 2022-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $164.63 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $130.78 | 2022 | |
| Abbvie INC. | $114.02 | 2022-2025 | |
| Abbott Laboratories | $108.51 | 2022-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $100.16 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $95.58 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Bayer Healthcare Pharmaceuticals INC. | $93.77 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $93.10 | 2022-2023 | Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $78.16 | 2022-2023 | Xarelto |
| Novo Nordisk INC | $74.45 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Ucb, INC. | $68.61 | 2024 | Briviact |
| Idorsia Pharmaceuticals US INC | $41.00 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $32.03 | 2022-2023 | Austedo Xr |
| Mayne Pharma Commercial LLC | $31.97 | 2025 | |
| Verity Pharmaceuticals INC. | $30.33 | 2024-2025 | Tlando |
| Sanofi Pasteur INC. | $22.31 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.63 | 2023 | |
| Eisai INC. | $17.79 | 2022 | |
| Esperion Therapeutics, INC. | $16.73 | 2022 | |
| Dexcom, INC. | $16.38 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $16.23 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $14.66 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $13.52 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Terzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.